Clinical Performance of the Osia 3 Sound Processor Compared With the Osia 2 Sound Processor in Adult Osia Implant Users

Last updated: January 18, 2026
Sponsor: Cochlear
Overall Status: Completed

Phase

N/A

Condition

Deafness

Hearing Impairment

Hearing Loss

Treatment

Cochlear Osia 3 Sound Processor

Cochlear™ Osia® 2 Sound Processor

Clinical Study ID

NCT06338670
CLTD5839
  • Ages > 18
  • All Genders

Study Summary

This study aims to investigate the clinical performance of the Osia 3 Sound Processor in comparison to the Osia 2 Sound Processor in adults with mixed or conductive hearing loss or single-sided deafness implanted with an Osia implant. Participants will attend four study visits, where they will complete various hearing assessments using the Osia sound processors.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Implanted with a Cochlear Osia Implant (OSI100 or OSI200)

  • Conductive or mixed hearing loss in the implanted ear. Bone conduction threshold 4-frequency pure tone average (PTA4; mean of bone conduction thresholds at 0.5, 1, 2and 4 kHz) ≤ 55 dB HL.

OR Single-Sided Deafness in the implanted ear. Air Conduction threshold 4-frequency pure tone average (PTA4; mean of air conduction thresholds at 0.5, 1, 2 and 3 kHz) ≤ 20 dB HL in the good ear.

  • Aged 18 years or older, at time of consent.

  • Minimum experience of 1 month with the Osia 2 Sound Processor.

  • Fluent speaker in the language used to assess speech perception performance.

  • Willing and able to provide written informed consent.

  • For voluntary visit Aqua+ in water only: Be comfortable with going into a swimmingpool and putting head under water.

Exclusion

Exclusion Criteria:

  • Sensitivity to loud sounds.

  • Ongoing infection at or around the sound processor area.

  • Unable or unwilling to comply with the requirements of the clinical investigation asdetermined by the Investigator.

  • Use of ototoxic drugs that could be harmful to the hearing, as judged by theinvestigator

  • Investigator site personnel directly affiliated with this study and/or theirimmediate families; immediate family is defined as a spouse, parent, child, orsibling.

  • Cochlear employees or employees of Contract Research Organisations or contractorsengaged by Cochlear for the purposes of this investigation.

  • Current participation, or participation in another interventional clinicalstudy/trial in the past 30 days, involving an investigational drug or device (unlessthe other investigation was/is a Cochlear sponsored investigation and determined bythe investigator or Sponsor to not impact this investigation).

Study Design

Total Participants: 12
Treatment Group(s): 2
Primary Treatment: Cochlear Osia 3 Sound Processor
Phase:
Study Start date:
July 04, 2024
Estimated Completion Date:
July 23, 2025

Connect with a study center

  • The HEARing CRC

    Melbourne, Victoria 3053
    Australia

    Site Not Available

  • The HEARing CRC

    Melbourne 2158177, Victoria 2145234 3053
    Australia

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.